School of Medicine
Showing 101-150 of 163 Results
-
Dhriti Nagar
Postdoctoral Scholar, Neonatal and Developmental Medicine
BioPremature birth is a leading cause of developmental and neuropsychiatric disorders in children. One of the factors causing these defects is lowered levels of available oxygen (hypoxia) in the newborn due to immature lungs. My research focuses on understanding the cellular and molecular mechanisms underlying hypoxia-induced developmental disorders of the nervous system due to preterm birth.
-
Anca M. Pasca, MD
Assistant Professor of Pediatrics
Current Research and Scholarly InterestsThe research focus of the lab is to understand molecular mechanisms underlying neurodevelopmental disorders associated with premature birth, neonatal and fetal brain injury with the long-term goal of translating the lab’s findings into therapeutics. The research team employs a multidisciplinary approach involving genetics, molecular and developmental neurobiology, animal models and neural cells differentiated from patient-derived induced pluripotent stem (iPS) cells. In particular, the lab is using a powerful 3D human brain-region specific organoid system developed at Stanford (Nature Methods, 2015; Nature Protocols, 2018) to ask questions about brain injury during development.
https://www.neopascalab.org/ -
Lance Prince
Philip Sunshine, MD, Professor of Neonatology
BioLawrence (Lance) S. Prince, MD, PhD, is the Division Chief for Neonatal and Developmental Medicine at Stanford School of Medicine. Dr. Prince was previously a Professor of Pediatrics and Chief of the Division of Neonatology at the University of California, San Diego and Rady Children’s Hospital, San Diego.
Dr. Prince has a long and distinguished career mentoring clinical and scientific trainees and students, many of whom have gone on to establish their own successful careers as academic physician investigators. As a physician scientist, Dr. Prince leads a basic science laboratory focusing on the mechanisms regulating developmental immunology and lung injury and repair. Dr. Prince received a Bachelor of Science in Chemistry from University of Miami, an MD/PhD with a focus in Cell Biology from University of Alabama at Birmingham, and postdoctoral fellowship, Pediatrics residency, and Neonatal-Perinatal Medicine Fellowship training at the University of Iowa. Before arriving in California, Dr. Prince was an Associate Professor of Pediatrics at Vanderbilt University.
Dr. Prince’s research interests include the molecular and cellular mechanisms controlling lung development and the maturation of the fetal and neonatal immune systems. He has a particular clinical interest in managing and treating neonatal lung diseases, especially bronchopulmonary dysplasia (BPD) in babies born extremely preterm. Dr. Prince’s research team focuses primarily on the development of innate immunity during fetal life as it impacts health and disease in preterm infants. The laboratory is investigating how microbes including Group B streptococcus exploit the unique features of neonatal macrophages to avoid immune detection and cause disease, as well as leading a number of clinical and translational investigations. -
Jochen Profit
Wendy J. Tomlin-Hess Endowed Professor
Current Research and Scholarly InterestsFunded by NIH R01 grants:
1) Development and application of composite measure of NICU quality - Baby-MONITOR
2) High reliability, safety culture and caregiver resilience as modifiers of care quality
3) Modifiable racial/ethnic disparities in quality of care delivery
4) Effectiveness of regionalized care delivery systems for preterm newborns -
Nilima Ragavan
Clinical Professor, Pediatrics - Neonatal and Developmental Medicine
BioDr Nilima Ragavan is an experienced clinician who has expertise in the care of newborns ranging from critically ill to well babies. She is passionate about education and is the director of the Stanford pediatric resident rotation in the neonatal intensive care unit. She has led several multi disciplinary teams to India, and has organized and conducted international neonatal and perinatal conferences. She is a member of the palliative care team and serves as a mentor to junior faculty. She is the medical director of the Packard Special Care nursery at Sequoia, and also attends in the NICU at Stanford.
-
Anoop Rao
Clinical Assistant Professor, Pediatrics - Neonatal and Developmental Medicine
Current Research and Scholarly InterestsWearable senors, unobtrusive vital sign monitoring, natural language processing/text mining
-
William Rhine
Professor of Pediatrics (Neonatology)
Current Research and Scholarly InterestsNeonatology, extracorporeal membrane oxygenation, nitric oxide therapy, mechanisms of bilirubin toxicity and brain injury, non-invasive biotechnologies to study cellular and organ metabolism.
-
Meera N. Sankar
Clinical Professor, Pediatrics - Neonatal and Developmental Medicine
Current Research and Scholarly InterestsPDA in premature infants
Transcutaneous bilirubin use in the NICU Setting -
Michael Scahill
Clinical Assistant Professor, Pediatrics - Neonatal and Developmental Medicine
BioOn a trip to Mozambique while in med school here at Stanford, I saw the power of market interventions to improve population health. In Pediatric Leadership for the Underserved residency at UCSF, I helped Jacaranda Health establish their pediatric clinic in Nairobi. Now, I split my time between the Stanford NICU and Virta, where I direct the digitally delivered diabetes reversal clinic.
-
Gary M. Shaw
NICU Nurses Professor and Professor (Research), by courtesy, of Epidemiology and Population Health and of Obstetrics and Gynecology (Maternal Fetal Medicine)
Current Research and Scholarly InterestsPrimary research interests include 1) epidemiology of birth defects, 2) gene-environment approaches to perinatal outcomes, and 3) nutrition and reproductive outcomes.
-
David K. Stevenson, M.D.
Harold K. Faber Professor of Pediatrics, Senior Associate Dean, Maternal and Child Health and Professor, by courtesy, of Obstetrics and Gynecology
Current Research and Scholarly InterestsOur research is focused on the study of the ontogeny and control of heme catabolism and bilirubin production in the developing neonate. A better understanding of the role of increased bilirubin production in neonatal jaundice and the prevention of hemolytic jaundice has remained an overall objective of our program. We are also study the causes of preterm birth and ways to prevent it.
-
George F Tidmarsh
Adjunct Professor, Pediatrics - Neonatology
BioDr. Tidmarsh received M.D. and Ph.D. from Stanford University, where he also completed fellowship training in Pediatric Oncology and Neonatology and is currently Adjunct Faculty of Pediatrics and Neonatology. He served as clinical faculty at Stanford for a number of years after fellowship prior to devoting his full time to clinical research and development in order to bring new treatments through the FDA approval process. Dr. Tidmarsh was President, Chief Executive Officer, Secretary and a Director of La Jolla Pharmaceutical Company from January 2012 until November 2019. While at La Jolla, Dr. Tidmarsh helped discover the use of angiotensin II for the treatment of shock and led all aspects of the development including approval by the US FDA and the EMA for the treatment of patients suffering from distributive shock. He also led the development of artesunate for the treatment of severe malaria, now pending action for potential approval at the FDA. Dr. Tidmarsh has over 30 years of experience in biotechnology, including the successful clinical development of three FDA-approved drugs. He previously served as the Chief Executive Officer of Horizon Pharma, Inc., a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of rheumatoid arthritis. He also founded Threshold Pharmaceuticals, Inc. and held senior positions at Coulter Pharmaceutical, Inc. (acquired by GlaxoSmithKline) and SEQUUS Pharmaceuticals, Inc. (acquired by Johnson & Johnson). While at Coulter and SEQUUS, Dr. Tidmarsh led the clinical development of BEXXAR and Doxil, respectively, two FDA-approved anti-cancer agents.
At Stanford, Dr. Tidmarsh is devoted to teaching clinical research and development to residents, fellows and junior faculty. In addition, he is working to help improve the quality of medical care through various efforts which include serving on the board of Lucile Packard Foundation for Children's Health.